Presentations will feature results from the NHS-Galleri and PATHFINDER 2 studies involving more than 174,000 participants.

GRAIL will present additional data from the NHS-Galleri trial and the PATHFINDER 2 study at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The presentations will further evaluate the Galleri multi-cancer early detection (MCED) test during the event held May 29 to June 2, 2026, in Chicago.

The NHS-Galleri trial presentation will expand on topline results announced in February 2026. As a randomized controlled study of an MCED test, it was designed to demonstrate population-level impact through the reduction of late-stage cancer diagnosis and increased cancer detection rates within the National Health Service (NHS) in England. The trial evaluated annual screening with the Galleri test in addition to standard of care screening over three years in more than 142,000 participants aged 50 to 77.

The complete dataset from the PATHFINDER 2 study, which includes more than 32,000 evaluable participants, will also be presented. Conducted under a Food and Drug Administration (FDA)-approved investigational device exemption, PATHFINDER 2 is an MCED interventional study in North America focused on an intended-use population with no clinical suspicion of cancer.

“These results from NHS-Galleri and PATHFINDER 2, two large, rigorous studies, underscore Galleri’s strong performance, ability to shift detection of cancers earlier before metastatic disease, and strong safety profile,” says Josh Ofman, president of GRAIL, in a release. “We look forward to sharing these findings, which strengthen the body of evidence supporting the clinical utility, performance, and safety of Galleri in intended-use populations and reflect GRAIL’s extensive experience building a robust evidence base for multi-cancer early detection.”

Additional data will include a poster presentation on the implementation of the MCED test in private practice settings. This study examines adoption, performance, and repeat-testing patterns for the blood-based screening tool.

The GRAIL clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. While the Galleri test is intended for clinical purposes, it has not been cleared or approved by the FDA. The test is currently recommended for adults with an elevated risk for cancer, such as those aged 50 or older, and is intended to be used in addition to routine cancer screening tests.

Photo caption: Galleri test

Photo credit: File/GRAIL

Related Reading: